Tadalafil Tablet
Product Images NDC 70518-4605

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 70518-4605). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (30ee4705 36a5 4a56 852d 9d76c40668db 01)

Chemical structure of the active ingredient Tadalafil, showing its molecular framework with multiple rings including a benzene and indole moiety, and functional groups such as amide and methyl groups.*

FDA Label Image

Figure 1 (30ee4705 36a5 4a56 852d 9d76c40668db 02)

A set of four line graphs showing blood pressure differences (Tadalafil minus Placebo) over time in hours. The charts include Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, each with error bars depicting variability across time points up to 96 hours.*

FDA Label Image

Figure 2 (30ee4705 36a5 4a56 852d 9d76c40668db 03)

A line graph displaying changes in standing and supine systolic blood pressure (mmHg) over 24 hours post-dose. It compares Tadalafil 20 mg with doxazosin 8 mg to placebo with doxazosin 8 mg. The x-axis shows time post-dose (hours), and the y-axis shows systolic BP changes, with two subplots for standing and supine measurements.*

FDA Label Image

Figure 3 (30ee4705 36a5 4a56 852d 9d76c40668db 04)

A line graph showing systolic blood pressure changes (mmHg) over 12 hours after administration of 20 mg tadalafil or placebo, each combined with 8 mg doxazosin at 08:00 or 20:00. Four data series compare blood pressure effects across these different dosing times and treatments.*

FDA Label Image

Figure 4 (30ee4705 36a5 4a56 852d 9d76c40668db 05)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours). It includes three data series: single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. Concentrations peak early and decline over time, with error bars representing variability for each time point.*

FDA Label Image

Figure 5 (30ee4705 36a5 4a56 852d 9d76c40668db 06)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment for Tadalafil 5 mg versus placebo. The graph shows a greater decrease in IPSS score for Tadalafil 5 mg at weeks 4, 8, and 12, with statistical significance indicated at week 12 (p < 0.01). The x-axis represents treatment duration (weeks), and the y-axis represents change from baseline in IPSS total score.*

FDA Label Image

Figure 6 (30ee4705 36a5 4a56 852d 9d76c40668db 07)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks, and the y-axis shows the change in IPSS total score. The graph indicates greater improvement with Tadalafil compared to placebo, with significant differences marked at weeks 4 and 12.*

FDA Label Image

Figure 7 (30ee4705 36a5 4a56 852d 9d76c40668db 08)

Line graph showing least-squares mean change from baseline over weeks of therapy (0, 4, 12, 26) for two treatment groups: Tadalafil/Finasteride and Placebo/Finasteride. The graph illustrates greater reduction in mean change for Tadalafil/Finasteride across time points, with statistical annotations for significance.*

FDA Label Image

Figure 8 (30ee4705 36a5 4a56 852d 9d76c40668db 09)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg and placebo groups. The x-axis represents treatment duration in weeks, and the y-axis shows the change from baseline. Two lines indicate the scores for Tadalafil 5 mg and placebo, with Tadalafil showing a greater decrease over time. Statistical significance is noted at week 12.*

FDA Label Image

Remedy_label (Remedy Label)

Tadalafil 5 mg tablet label showing a quantity of 1 tablet. The label includes the NDC number 70518-4605-01 and mentions repackaging by RemedyRepack Inc., Indiana, PA. Storage instructions recommend 20-25°C with permitted excursions to 15-30°C. The label also includes manufacturer information for Torrent, India.*

FDA Label Image

Mm1 (Tadalafil 5mg 70518 4605 00)

The label is for Tadalafil Tablet 5 mg strength, in a box containing 50 tablets. The product is repackaged by RemedyRepack Inc., Indiana, PA, and labeled for prescription use (RX ONLY). Storage instructions include keeping out of reach of children and storing at 20-25°C with permitted excursions. The label includes an NDC number 70518-4605-00 and mentions the manufacturer is Torrent, Bharuch, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.